Abstract
Background Acute respiratory distress syndrome (ARDS) is associated with high mortality in Intensive Care Units (ICU). A previous genome-wide association study (GWAS) identified the vascular endothelial growth factor receptor 1 (VEGFR1) gene in ARDS risk. We performed a GWAS on soluble VEGFR1 (sVEGFR1) levels to identify protein quantitative trait loci (pQTLs) and genes of interest for ARDS.
Methods Serum samples (n=292) within the first 24 (T1), 72 hours (T2), and 7 days (T7) after sepsis diagnosis were collected while in the ICU. sVEGFR1 levels were measured and tested for association. We combined fine mapping, colocalisation and gene-set mapping analyses to prioritise genes and test low-frequency variation association with ARDS (n=822). We analysed the association of sVEGFR1 pQTLs with mortality and ARDS susceptibility using polygenic scores (PGS). Finally, the causality of VEGFR1 in ARDS was assessed using two-sample Mendelian randomisation (MR) analyses.
Results We found a pQTL for T2 sVEGFR1 levels at TCF20 (rs134871, p=4.66×10-8). Fine mapping prioritised rs762995 as a likely pathogenic variant and CYP2D6 as the most likely functional gene. The locus colocalised with eQTLs for TCF20 and CYP2D6. Low-frequency missense variation in TCF20 was associated with sepsis-associated ARDS susceptibility (p=3.0×10-3). sVEGFR1 levels PGS were associated with decreased ARDS susceptibility and mortality. MR analyses did not evidence causality.
Conclusions We identified biologically relevant pQTLs of VEGFR1 levels during sepsis in TCF20 and identified CYP2D6 as the gene more biologically implicated. Low frequency missense variation in TCF20 and sVEGFR1 levels PGS models were associated with sepsis outcomes.
What is already known on this topic Acute respiratory distress syndrome (ARDS) is an acute condition, characterised by respiratory failure, an acute inflammatory response and the development of non-cardiogenic oedema. There is a need for target pharmacological strategies and advances in the risk stratification methods that can improve patient management.
What this study adds We performed the first GWAS of sVEGFR1 levels in patients with sepsis. The integration of different complementary genomic approaches has allowed us to reveal a regulatory variant of sVEGFR1 during sepsis, suggesting a role in ARDS susceptibility and mortality. In exome-wide low-frequency variation analyses, we identified TCF20 as a novel gene of interest for ARDS.
How this study might affect research, practice or policy This study emphasises the value of proteogenomic approaches in improving our understanding of ARDS pathogenesis and detecting novel risk genes to advance patient risk stratification.
Competing Interest Statement
LVW reports research funding from GlaxoSmithKline (GSK), Genentech and Orion Pharma, and consultancy for Galapagos, and GSK. MT reports research funding from GSK and Orion Pharma. The other authors have declared no conflicts of interest.
Funding Statement
Instituto de Salud Carlos III (PI19/00141, PI20/00876, PI23/00980, CB06/06/1088 and AC21_2/00039), co-financed by the European Regional Development Funds, ‘A way of making Europe’ from the EU; ITER agreement (OA23/043); Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC21/36); Agencia Canaria de Investigación, Innovación y Sociedad de la Información de la Consejería de Economía, Conocimiento y Empleo y por el Fondo Social Europeo (FSE) Programa Operativo Integrado de Canarias 2014-2020, Eje 3 Tema Prioritario 74 (85%) Gobierno de Canarias, Social European Fund ‘Canarias Avanza con Europa’ (TESIS2022010042, TESIS2021010046), and Social European Fund Plus (EST2023010007), FIISC (PIFIISC23/05), Wellcome Trust (221680/Z/20/Z). The research was partially supported by the NIHR Leicester Biomedical Research Centre and through an NIHR Senior Investigator Award to M.D.T.; views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in the design of the study. M.D.T and L.V.W are also supported by Wellcome Trust Discovery Award WT225221/Z/22/Z. This research includes use of the UK Biobank through application 648 and the ALICE High Performance Computing Facility at the University of Leicester.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee for Drug Research from the Hospital Universitario de Canarias (Code: CHUNSC_2021-40) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos